



Pfizer Announces a [Research Grant RFP](#)

Burden of Pneumococcal Disease - Analyzing Local Surveillance Data

Competitive Grant Program - internal Pfizer review process

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

II. Eligibility

| | |
|---------------------------------------|--|
| Geographic Scope: | <ul style="list-style-type: none"> Asia, Africa, Latin America, and Middle East. |
| Applicant Eligibility Criteria | <ul style="list-style-type: none"> The institution and principal investigator (PI) must be based in one of the eligible countries in the regions noted above. Only organizations are eligible to receive grants, not individuals or medical practice groups. The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. Applicant must be affiliated with a host institution. |

III. Requirements

| | |
|---|---|
| Date RFP Issued: | <ul style="list-style-type: none"> July 28, 2021 |
| Clinical Area: | <ul style="list-style-type: none"> Pneumococcal Conjugate Vaccine |
| General Area of Interest for this RFP: | <p>Proposals that will be considered for Pfizer support should focus on the review and analysis of retrospective, local source surveillance of the pneumococcal disease burden and / or serotype distribution, whether in children or adults, as determined before, during, or following the implementation of a pneumococcal conjugate vaccine immunization program.</p> <p>Local surveillance data from country settings that are under-represented in the international, peer-reviewed medical literature will be given priority.</p> <p>Projects submitted should be based on surveillance data from:</p> <ul style="list-style-type: none"> National- or subnational-level publications (including local language publications). Publicly available surveillance reports at the national- or subnational-level, which includes hospitals, public health organizations, or academic settings (such as universities or educational institutions). <p>Disease burden to be considered includes:</p> <ul style="list-style-type: none"> Invasive pneumococcal disease (IPD), such as pneumococcal sepsis / bacteremia, meningitis, or bacteremic pneumonia. Non-invasive pneumococcal disease, such as pneumonia (or more broadly lower respiratory infection) or acute otitis media. Other presentations of pneumococcal disease, such as empyema, |

| | |
|--|---|
| | <p>sinusitis, peritonitis, osteoarticular infection, hemolytic uremic syndrome, septic arthritis, endocarditis, etc.</p> <p>Additional aspects that may be considered for quantitation of the disease burden of pneumococcal disease include:</p> <ul style="list-style-type: none"> • The impact of established risk factors or identification of new risk factors. • Exacerbations of underlying chronic diseases (e.g., congestive heart failure, diabetes, others) or long-term declines in the quality of life. <p>It is anticipated that the awardee will submit these assembled surveillance results as a manuscript to a peer-reviewed journal, to add eventually to the publicly available knowledge about pneumococcal disease epidemiology.</p> <p>References:</p> <ul style="list-style-type: none"> • Arjun R, Ratheesh RS, Mohan V, Uduman S, Jalaludeen S, Prabhakaran A, et al. Susceptibility and serotypes of Streptococcus pneumoniae isolates in invasive pneumococcal disease: a study from Kerala, South India. <i>Infez Med.</i> 2020;28(4):558-64. • Karstaedt AS, Khoosal M, Crewe-Brown HH. Pneumococcal bacteremia in adults in Soweto, South Africa, during the course of a decade. <i>Clin Infect Dis.</i> 2001;33(5):610-4. • Man MY, Shum HP, Yu JSY, Wu A, Yan WW. Burden of pneumococcal disease: 8-year retrospective analysis from a single centre in Hong Kong. <i>Hong Kong Med.</i> 2020;26(5):372-81. |
| <p>Expected Approximate Monetary Range of Grant Applications:</p> | <ul style="list-style-type: none"> • Individual projects requesting up to \$40,000 for a 1-year project will be considered. • The estimated total available budget related to this RFP is \$300,000. |
| <p>Key Dates:</p> | <ul style="list-style-type: none"> • RFP release date: July 28, 2021 • Grant Application due date: September 22, 2021 • Please note the deadline is 23:59 Eastern Standard Time (e.g. New York, GMT -5). • Anticipated Grant Award Notification Date: October 2021 • Grants will be distributed following a fully executed agreement. • Anticipated Project Start date: November 2021 • Project End date: one year upon contract execution |
| <p>How to Submit:</p> | <ul style="list-style-type: none"> • Please go www.cybergrants.com/pfizer/Research and sign in. First-time users should click "Create your password". <i>[Note: there are individual portals for each grant application type (e.g., knowledge, LOI, research full</i> |

| | |
|---|--|
| | <p><i>proposal, and QI full proposal). Please be sure to use the URL above.]</i></p> <ul style="list-style-type: none"> • Click the “Start A New Research Grant Application” button. • In the application: <ul style="list-style-type: none"> ○ For the question “Competitive Grant?” select Yes ○ Select the following Competitive Grant Program Name: “2021 VAC R: Burden of Pneumococcal Disease - Analyzing Local Surveillance Data” ○ Select the following Primary Area of Interest: Vaccine Preventable Disease - Pneumococcal • Requirements for submission: Complete all required sections of the online application and upload your project proposal (see Appendix) in the Proposal/Protocol field. • If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page. <p>IMPORTANT: Be advised applications submitted after the due date will not be reviewed.</p> |
| <p>Questions:</p> | <ul style="list-style-type: none"> • If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Miguel Briceno (miguelangel.briceno@pfizer.com) with the subject line “<i>Burden of Pneumococcal Disease - Analyzing Local Surveillance Data</i>” • Please click here to view Frequently Asked Questions regarding the Competitive Grant Program |
| <p>Grant Agreements:</p> | <ul style="list-style-type: none"> • If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement. • Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety. |
| <p>Review and Approval Process</p> | <ul style="list-style-type: none"> • Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions. |
| <p>Mechanism by which Applicants will be Notified:</p> | <ul style="list-style-type: none"> • All applicants will be notified via email by the dates noted above. • Applicants may be asked for additional clarification during the review period. |

Appendix A

General RFP Submission Requirements

Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

| | |
|---|---|
| Goals and Objectives | <ul style="list-style-type: none"> • Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective |
| Assessment of Need for the Project | <ul style="list-style-type: none"> • This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question |
| Target Audience | <ul style="list-style-type: none"> • Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population • Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population |
| Project Design and Methods | <ul style="list-style-type: none"> • Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan |
| Innovation | <ul style="list-style-type: none"> • Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project |
| Evaluation and Outcomes | <ul style="list-style-type: none"> • Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures • Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines |
| Anticipated Project Timeline | <ul style="list-style-type: none"> • Provide an anticipated timeline for your project including project start/end dates |
| Additional Information | <ul style="list-style-type: none"> • If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here • Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's career |

| | |
|----------------------------|---|
| Organization Detail | <ul style="list-style-type: none">• This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project |
| Budget Detail | <ul style="list-style-type: none">• The budget amount requested must be in U.S. dollars (USD).• While estimating your budget please keep the following items in mind:<ul style="list-style-type: none">○ Institutional overhead and indirect costs may be included within the grant request. Examples include human resources department costs, payroll processing and accounting costs, janitorial services, utilities, property taxes, property and liability insurance, and building maintenance as well as additional project expenses such as costs for publication, IRB / IEC review fees, software license fees, and travel. Please note: Pfizer does not provide funding for capital equipment.○ The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.○ It should be noted that grants awarded through GMG cannot be used to purchase therapeutic agents (prescription or non-prescription).• Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. |
| References | <ul style="list-style-type: none">• Bibliography of relevant references. |